New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 10, 2012
09:06 EDTMACKMerrimack announces positive clinical data for agent to treat breast cancer
Merrimack announced Phase I clinical trial results for MM-302, the company's agent for the treatment of advanced HER2 positive breast cancer. The findings demonstrated preliminary safety and tolerability.
News For MACK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 30, 2014
08:09 EDTMACKMerrimack presents additional Phase 2 biomarker data for MM-121
Subscribe for More Information
September 26, 2014
10:10 EDTMACKMerrimack management to meet with Brean Capital
Subscribe for More Information
05:40 EDTMACKPharmaEngine, Merrimack Pharmaceuticals amend MM-398 license agreement
Subscribe for More Information
September 24, 2014
09:05 EDTMACKOn The Fly: Pre-market Movers
Subscribe for More Information
07:39 EDTMACKMerrimack to hold a conference call
Conference call to discuss the exclusive license and collaboration agreement with Baxter International for the development and commercialization of MM-398 also known as "nal-IRI" will be held on September 24 at 8:30 am. Webcast Link
07:06 EDTMACKBaxter, Merrimack enter exclusive ex-U.S. licensing deal for MM-398
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use